ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse? Hematology Am Soc Hematol Educ Program 2009:414-8
Date
12/17/2009Pubmed ID
20008227DOI
10.1182/asheducation-2009.1.414Scopus ID
2-s2.0-77949447691 (requires institutional sign-in at Scopus site) 28 CitationsAbstract
A 35-year-old male with a FLT3(+) AML underwent allogeneic peripheral blood stem cell transplant using a myeloablative non-total body irradiation (TBI) conditioning regimen from his HLA-matched sibling donor. Following transplantation, he developed grade II acute graft-versus-host disease (GVHD) that resolved with increasing immunosuppression. The medications were subsequently discontinued, and he did not develop any evidence of chronic GVHD. Eighteen months after transplant, while off all immunosuppression, he developed fatigue and a blood count showed circulating blasts consistent with relapse of his disease. Among the various therapeutic questions is whether there is a role for a second allogeneic transplant to treat his disease and if so, at what time, with what conditioning, and with which type of donor.
Author List
Thakar MS, Forman SJMESH terms used to index this publication - Major topics in bold
Acute DiseaseAdult
Evidence-Based Medicine
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
Immunosuppressive Agents
Leukemia, Myeloid
Male
Practice Guidelines as Topic
Recurrence
Reoperation
Tissue Donors
Transplantation, Homologous
fms-Like Tyrosine Kinase 3
